» Articles » PMID: 16611266

Review Article: Intestinal Serotonin Signalling in Irritable Bowel Syndrome

Overview
Date 2006 Apr 14
PMID 16611266
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

Alterations in motility, secretion and visceral sensation are hallmarks of irritable bowel syndrome. As all of these aspects of gastrointestinal function involve serotonin signalling between enterochromaffin cells and sensory nerve fibres in the mucosal layer of the gut, potential alterations in mucosal serotonin signalling have been explored as a possible mechanism of altered function and sensation in irritable bowel syndrome. Literature related to intestinal serotonin signalling in normal and pathophysiological conditions has been searched and summarized. Elements of serotonin signalling that are altered in irritable bowel syndrome include: enterochromaffin cell numbers, serotonin content, tryptophan hydroxylase message levels, 5-hydroxyindoleacedic acid levels, serum serotonin levels and expression of the serotonin-selective reuptake transporter. Both genetic and epigenetic factors could contribute to decreased serotonin-selective reuptake transporter in irritable bowel syndrome. A serotonin-selective reuptake transporter gene promoter polymorphism may cause a genetic predisposition, and inflammatory mediators can induce serotonin-selective reuptake transporter downregulation. While a psychiatric co-morbidity exists with IBS, changes in mucosal serotonin handling support the concept that there is a gastrointestinal component to the aetiology of irritable bowel syndrome. Additional studies will be required to gain a more complete understanding of changes in serotonin signalling that are occurring, their cause and effect relationship, and which of these changes have pathophysiological consequences.

Citing Articles

Assessment of Urinary Dopamine and Serotonin Metabolites in Relation to Dysbiosis Indicators in Patients with Functional Constipation.

Chojnacki J, Poplawski T, Kaczka A, Romanowska N, Chojnacki C, Gasiorowska A Nutrients. 2024; 16(17).

PMID: 39275296 PMC: 11397005. DOI: 10.3390/nu16172981.


Investigation of the causal association between Parkinson's disease and autoimmune disorders: a bidirectional Mendelian randomization study.

Yang J, Lin W, Ma Y, Song H, Mu C, Wu Q Front Immunol. 2024; 15:1370831.

PMID: 38774879 PMC: 11106379. DOI: 10.3389/fimmu.2024.1370831.


Systematic Review on Herbal Preparations for Controlling Visceral Hypersensitivity in Functional Gastrointestinal Disorders.

Lashgari N, Roudsari N, Momtaz S, Niazi Shahraki F, Zandi N, Pazoki B Curr Pharm Biotechnol. 2024; 25(13):1632-1650.

PMID: 38258770 DOI: 10.2174/0113892010261502231102040149.


Modulation of Intestinal Motility in an Adolescent Rat Model of Irritable Bowel Syndrome.

Kyodo R, Kudo T, Ito N, Tokita K, Arai N, Sato M Digestion. 2023; 105(2):99-106.

PMID: 37963446 PMC: 10994574. DOI: 10.1159/000534732.


A model for irritable bowel syndrome and anxiety comorbidities in relation to alcohol use disorders.

Vashkevich K, Janiuk K, Maleki N Front Med (Lausanne). 2023; 10:1161130.

PMID: 37293305 PMC: 10244726. DOI: 10.3389/fmed.2023.1161130.